Core One Labs Inc. - CEO, Joel Shacker

" Core One Labs (CSE:COOL) acquires Awakened Biosciences and its patents

Core One Labs Inc. (COOL) has acquired all outstanding share capital of Awakened Biosciences for $9.76 million.

" Core One Labs (CSE:COOL) subsidiary Akome Biotech signs research agreement with the University of Barcelona

Core One Labs (COOL) subsidiary Akome Biotech has signed a consulting agreement with the University of Barcelona.

" Core One Labs (CSE:COOL) receives Health Canada approval for DMT

Health Canada has authorized Core One (COOL) to add DMT to its Controlled Drugs and Substances Act Dealer’s License.

" Core One Labs (CSE:COOL) acquires New Path Laboratories

Core One (COOL) has acquired New Path Laboratories, a developer of functional mushroom health products.

" Core One Labs (CSE:COOL) submits psilocybin psychedelic-assisted therapy application

Two Core One Labs (COOL) subsidiaries are helping a patient complete an application to legally access psilocybin for psychedelic-assisted therapy.

" Core One Labs (CSE:COOL) to host a presentation on its proprietary Biosynthetic Psilocybin Technology

Dr. Robert E.W. Hancock, Chairman and CEO of Core One (COOL) subsidiary Vocan Biotechnologies will be presenting at a virtual town hall meeting.

" Core One Labs (CSE:COOL) announces details of consolidation to meet Nasdaq requirements

Core One Labs (COOL) announced the company is pursuing a listing on the Capital Market tier of The Nasdaq Stock Market LLC.

" Core One Labs (CSE:COOL) subsidiary developing psychedelic drug formulation AKO001

Core One Labs (COOL) subsidiary Akome Biotech Ltd. is developing a psychedelic drug formulation to reduce neurological damage resulting from ischemic strokes.

" Core One Labs (CSE:COOL) plans share consolidation in preparation for Nasdaq listing

In preparation for a potential listing of its common shares on Nasdaq, Core One Labs (COOL) is planning a share consolidation.

" Core One Labs (CSE:COOL) subsidiary patenting biosynthesized psilocybin

Core One Labs (COOL) subsidiary Vocan Biotechnologies is finalizing its provisional patent application for biosynthetic psilocybin production.

" Core One Labs (CSE:COOL) commences development on psychedelic drug formulation for the treatment of Alzheimer’s Disease

Core One Labs (COOL) newly acquired subsidiary Akome Biotech is developing a psychedelic drug formulation for the treatment of Alzheimer’s Disease.

" World-renowned physician joins Core One Labs (CSE:COOL) as Chief Medical Officer

Core One Labs (COOL) has appointed Dr. Santiago Ferro, Chief Executive Officer of Akome Biotech Ltd. as Chief Medical Officer.

" Core One Labs (CSE:COOL) reaches agreement to acquire Akome Biotech

Core One Labs (COOL) has entered into a definitive share purchase agreement to acquire all of the outstanding shares of Akome Biotech Ltd. 

" Lobe Sciences (CSE:LOBE) enters into joint venture with Core One Labs (CSE:COOL) for the development of psychedelic compounds

Lobe Sciences has entered into a non-binding letter of intent with Core One Labs.

" Core One Labs (CSE:COOL) to explore joint venture with Lobe Sciences

Core One Labs Inc. (COOL) has entered into a letter of intent with Lobe Sciences Ltd.

" Core One Labs (CSE:COOL) subsidiary enters into collaborative research agreement with UBC

Core One Labs (COOL) subsidiary Vocan Biotechnologies has entered into a collaborative research agreement with UBC.

" Core One Labs’ (CSE:COOL) initiates the engineering and design of a proprietary production system

Core One Labs’ (COOL) subsidiary Vocan Biotechnologies has initiated the engineering and design of a production system to manufacture API-Grade N,N-dimethyltryptamine (DMT).